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Abstract
Background: Dysregulated PI3K/Akt signaling occurs commonly in breast cancers and is due to HER2 amplification, PI3K
mutation or PTEN inactivation. The objective of this study was to determine the role of Akt activation in breast cancer as a
function of mechanism of activation and whether inhibition of Akt signaling is a feasible approach to therapy.
Methodology/Principal Findings: A selective allosteric inhibitor of Akt kinase was used to interrogate a panel of breast
cancer cell lines characterized for genetic lesions that activate PI3K/Akt signaling: HER2 amplification or PI3K or PTEN
mutations in order to determine the biochemical and biologic consequences of inhibition of this pathway. A variety of
molecular techniques and tissue culture and in vivo xenograft models revealed that tumors with mutational activation of
Akt signaling were selectively dependent on the pathway. In sensitive cells, pathway inhibition resulted in D-cyclin loss, G1
arrest and induction of apoptosis, whereas cells without pathway activation were unaffected. Most importantly, the drug
effectively inhibited Akt kinase and its downstream effectors in vivo and caused complete suppression of the growth of
breast cancer xenografts with PI3K mutation or HER2 amplification, including models of the latter selected for resistance to
Herceptin. Furthermore, chronic administration of the drug was well-tolerated, causing only transient hyperglycemia
without gross toxicity to the host despite the pleiotropic normal functions of Akt.
Conclusions/Significance: These data demonstrate that breast cancers with PI3K mutation or HER2 amplification are
selectively dependent on Akt signaling, and that effective inhibition of Akt in tumors is feasible and effective in vivo. These
findings suggest that direct inhibition of Akt may represent a therapeutic strategy for breast and other cancers that are
addicted to the pathway including tumors with resistant to Herceptin.
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Introduction
The phosphatidylinositol 3-kinase (PI3K) enzyme family plays
key roles in the transduction of metabolic, proliferative and
survival signals induced by insulin and other growth factors [1].
Activated PI3K generates phosphatidylinositol 3,4,5-triphosphate
(PIP3), which binds to the pleckstrin-homology domain (PH-
domain) of multiple proteins and thus regulates their activity.
PI3K signaling is activated by growth factor receptors and
regulated and terminated by multiple factors including dephos-
phorylation of the 39phosphate of PIP3 by the phosphatase PTEN
[2]. Deregulation of the PI3K signaling pathway is a hallmark of
human cancer, perhaps occurring in a majority of tumors [3].
Mutation, amplification or overexpression of receptor tyrosine
kinases occurs in many cancers [4,5] and activation of PI3K has
been shown to be necessary for their ability to induce
transformation. Activating mutations of the gene that encodes
the catalytic subunit of class 1A PI3K (PIK3CA) have been
identified in significant numbers of breast, colorectal and other
tumors [6,7]. PTEN is a tumor suppressor gene that is mutationally
inactivated in many tumors and inhibited by post-translational
modification or decreased expression in others [8,9,10].
The mechanisms through which activated PI3K mediates the
transformed phenotype are incompletely understood and probably
involve multiple targets. The most well-characterized are the three
members of the Akt protein kinase family. Akt subserves many of
the metabolic and proliferative effects of RTK-PI3K signaling. It
phosphorylates several transcription factors, including members of
the Foxo family and inhibits their functions. Akt family members
also affect proliferation and survival by phosphorylating a variety
of other substrates that regulate Cap-dependent translation,
apoptosis and other processes [11]. Uncontrolled activation of
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to play an important role in maintaining their proliferation,
preventing apoptosis, and supporting processes required for the
metastatic phenotype [3].
In breast cancer, Akt is activated by a variety of mechanisms
that correlate with specific biologic subsets of the disease. Thus,
activating mutations of PIK3CA are common in breast cancers that
express estrogen receptor [12]. HER2 amplification defines a
second subtype of breast cancer in which PI3K/Akt signaling is
driven by active HER2/HER3 heterodimers [13,14]. In a third
subset, ‘triple negative’ cancers that express neither hormone
receptors nor high levels of HER2, PTEN is mutated rarely, but a
transcriptional profile associated with decreased PTEN function is
commonly expressed [15].
Akt is a retroviral oncogene and has oncogenic properties in
model systems [16]. Akt amplification has been demonstrated in
human ovarian cancer [17] and, recently, Akt1 mutations were
identified in human cancers [18]. These findings suggest that Akt
could be an important therapeutic target for human cancer. Many
attempts have been made to develop ATP-competitive inhibitors
of Akt kinase. Thus far, it has been difficult to generate compounds
with sufficient specificity, potency and in vivo activity [19,20].
Some classes of compounds have had what has been felt to be
unacceptable toxicity [19,20], perhaps unsurprising for inhibitors
of a protein with such pleiotypic and central regulatory functions.
An alternative approach for achieving selectivity in kinase
inhibitors is the development of antagonists that act allosterically
at sites distant from the catalytic domain [20]. Such inhibitors
could be more specific and potentially less toxic as a result of fewer
off-target activities. A family of Akt inhibitors that selectively
depend on the PH-domain of Akt for their inhibitory activity has
been developed [21]. We have now used one of these, a potent and
specific inhibitor of Akt1 and Akt2 (AKTi-1/2), to study the role of
Akt activation in breast cancers and to explore whether Akt
inhibition is feasible as a therapeutic strategy.
Our data shows that tumors with HER2 amplification or
PIK3CA mutation are selectively dependent on Akt signaling
compared to tumors in which the pathway is not mutationally
activated. Moreover, the allosteric Akt inhibitor effectively inhibits
Akt signaling in tumors in vivo and completely suppresses their
growth, without gross toxicity to the host. The results show that
Akt inhibition represents a promising strategy for the treatment of
the breast cancers that are dependent on this pathway.
Results
AKTi-1/2 is a potent and selective inhibitor of Akt1 and
Akt2
A potent and selective inhibitor of Akt1 and Akt2 (AKTi-1/2;
naphthyridinone) was prepared through optimization of leads
identified by a high-throughput screen for inhibitors of purified
activated Akt1, Akt2 and Akt3 kinases [21]. As is the case for the
previously described compounds in this class [22,23], AKTi-1/2 is
not competitive with ATP and its inhibitory activity requires the
presence of the PH domain [21]. The compound selectively
inhibited Akt1 and Akt2 with EC50 values of 3.5 nM and 42.1 nM,
respectively. It was 45-fold less active against Akt3 (EC50 1.9 mM)
and was essentially inactive against closely related AGC family
kinases (PKA, PKC, SGK, GSK, PDK1) at concentrations as high
as 10 mM [21]. In screens against total of 169 unique kinases, only
7 enzymes were inhibited more than 50% at 10 mM, none of
which are members of the PI3K/Akt/mTOR signaling cascade
(unpublished data). Thus, in vitro assays suggest that this
compound is a very specific inhibitor of Akt1 and Akt2.
Breast cancer cells with HER2 amplification or PI3K
mutation are sensitive to Akt inhibition
In a panel of breast cancer cell lines, those with PIK3CA
mutation [12], HER2 amplification [24] or undetectable levels of
PTEN expression [8,25] all displayed Akt activation as assessed by
elevated levels of Akt phosphorylation on threonine 308 and serine
473 (Figure 1A). In contrast, in five cell lines in which PTEN was
expressed, HER2 levels were low, and PIK3CA was wild-type,
levels of Akt phosphorylation were low (Figure 1A and Figure S1).
Akt1 and Akt2 proteins were expressed in all of the cell lines at
varying levels; Akt3, which is preferentially expressed in brain and
skin [26,27], was expressed only in two cell lines (MDA-MB-468
and MDA-MB-231) in the panel. AKTi-1/2 effectively and
completely inhibited Akt phosphorylation at 0.5–1 mM in each of
the cell lines in tissue culture except MDA-MB-468, in which
phosphorylation was inhibited 60% at 0.5 mM, but 5–10 mM was
required for maximal inhibition (Figure 1B).
The breast cancer cell lines with PI3KCA mutation or HER2
amplification were uniformly sensitive to AKTi-1/2 with IC50 of
0.1–0.88 mM (Figure 1A and Figure S1). In contrast, the five cell
lines without aberrant activation of PI3K signaling were all
insensitive to the drug, even at concentrations greater than 10 mM,
far exceeding those required for inhibition of Akt phosphorylation.
Thus, tumor cells in which a transforming event dysregulates Akt
signaling are hypersensitive, or ‘addicted’, to Akt inhibition
compared to tumor cells in which regulation of the pathway is
not impaired.
The situation in tumors with PTEN-deficiency is more complex.
ZR-75-1, a PTEN-deficient cell, is also sensitive to the inhibitor
(IC50 of 0.1 mM). In contrast, MDA-MB-468, a PTEN-deficient
cell with high levels of EGFR, is not (Figure 1A). This may be
explained by the high level expression of Akt3 in this tumor cell.
However, we have previously shown that PTEN-negative tumors
with elevated EGFR/MEK/ERK signaling are refractory to
inhibition of PI3K/Akt signaling alone, but sensitive to combined
inhibition of both pathways [28].
AKTi-1/2 inhibits Akt signaling and causes G1 arrest and
apoptosis
The marked sensitivity of PIK3CA-mutated and/or HER2-
overexpressing breast cancer cells to AKTi-1/2 allowed us to
examine the functional consequences of Akt blockade in these cells.
The effects of AKTi-1/2 on Akt signaling were compared in T47D,
atumorcellwiththe PIK3CAH1047R mutationandinHCC1806,a
tumor cell with normal AKT signaling that is insensitive to the drug
(Figure 2A). In both cells, 1 mM AKTi-1/2 effectively inhibited Akt
phosphorylation and the phosphorylation of the Akt substrate
Foxo3a and GSK3b as well as phosphorylation of the downstream
target of Akt-TORC1 signaling, p70S6K. In T47D, the phosphor-
ylation of other downstream targets of Akt signaling, S6 and 4EBP1
were also inhibited. Similar results were obtained in BT474 and
MDA-MB-453 cell lines with coexistent HER2 overexpression and
PIK3CA mutations (Figure 3A).
Inhibition of Akt signaling in T47D was associated with loss of
D-cyclin expression, induction of p27 and loss of Rb phosphor-
ylation. In contrast, in HCC1806, inhibition of Akt signaling
resulted in inhibition of neither both S6 and 4EBP1 phosphory-
lation nor in changes in D-cyclin or p27 expression and Rb
phosphorylation (Figure 2A). It is likely that in this cell, in which
Akt signaling is not activated by mutation, other pathways are
responsible for S6 and 4EBP1 phosphorylation and deregulation
of growth. As expected from these data, T47D cells treated with
1 mM AKTi-1/2 accumulated in the G1 phase of the cell cycle
Akt Addiction of Breast Cancer
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inhibition had no effect on the cell cycle of HCC1806 (Figure 2B).
The data support the conclusion that activation of PI3K/Akt
signaling by HER2/HER3 signaling plays a key role in mediating
the transformed phenotype in breast cancers with HER2
amplification [13,14]. Furthermore, these tumors often harbor
coexistent PIK3CA mutations [12], further suggesting the impor-
tance of the pathway. In Figure 3, the effects of inhibition of Akt
activity with AKTi-1/2 were examined in more detail in tumors
with HER2-overexpression. In a panel of five cell lines, Akt
phosphorylation, phosphorylation of Akt substrates such as
GSK3a and members of the Foxo family, and phosphorylation
of downstream components of the pathway were inhibited
(Figure 3A and unpublished data). All of these cell lines underwent
G1 arrest which was maximal at 24 after exposure to the
compound (Figure 3B and unpublished data). G1 arrest was
followed by marked induction of apoptosis at 48–72 hours as
assessed by increased sub-G1 fraction or by increased levels of
cleaved PARP in cell lines with HER2 amplification with or
without coexistent PIK3CA mutation (SKBr3, MDA-MB-453,
UACC-893, MDA-MB-361 and BT474) (Figure 3A and 3C and
unpublished data). Thus, these cells are dependent on Akt
signaling for both proliferation and survival.
AKTi-1/2 effectively inhibits Akt signaling in vivo and has
profound anti-tumor activity
The in vitro data support the ideas that the dysregulation of
PI3K/Akt that is commonly found in human tumors is likely to be
essential for maintenance of the transformed phenotype and that
the pathway is therefore an appealing therapeutic target.
However, because PI3K/Akt signaling has many important
functions, including the maintenance of glucose homeostasis, it is
not clear that its inhibition would be tolerated in vivo. To
determine whether tolerable doses of AKTi-1/2 could effectively
inhibit Akt signaling in tumors in vivo and inhibit their growth,
mice harboring BT474 xenografts were treated with the drug.
Unlike UACC-893, MDA-MB-453 and MDA-MB-361, BT474
cells are highly tumorigenic when injected into nude mice. BT474
breast cancer cells overexpress HER2, harbor PIK3CA K111N
mutation [12], and respond to AKTi-1/2 in tissue culture in a
Figure 1. PIK3CA-mutated or HER2-overexpressing breast cancer cells are highly sensitive to AKTi-1/2. (A) Half-maximal growth
inhibitory concentration (IC50) of AKTi-1/2 to a panel of breast cancer cell lines with wild-type (wt) and mutant (mut) PIK3CA, PTEN loss, HER2 and EGFR
amplification (amp). Growth inhibition assays and Western blot analysis for expression of EGFR, HER2, Akt1, Akt2, Akt3, pan-Akt, PTEN, b-actin and
phosphorylated Akt at Ser473 and Thr308 were performed as described in Materials and Methods. (B) Western blot analysis of Ser473 phosphorylated
Akt and pan-Akt in cell lysates of the indicated breast cancer cells after treatment with various concentrations of AKTi-1/2 for 24 h.
doi:10.1371/journal.pone.0003065.g001
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overexpressing breast cancer cells (Figures 1 and 3).
Akt is a key downstream mediator of the metabolic effects of
insulin and hyperglycemia is a known side-effect of Akt inhibitors
[29]. AKTi-1/2 treatment of mice at a dose of 100 mg/kg caused
transient hyperglycemia that peaked 2 hours after drug adminis-
tration and that was associated with a transient hyperinsulinemia,
both of which resolved by 6–8 hours (manuscript in preparation).
Mice treated with 100 mg/kg AKTi-1/2 for 5 consecutive days
each week for 4–6 weeks demonstrated no gross toxicity or weight
loss (Figure S2 and unpublished data). At this dose, Akt
phosphorylation fell rapidly within 1 hour of drug administration
Figure 2. AKTi-1/2 inhibits Akt signaling and causes G1 arrest in PIK3CA-mutant but not in PIK3CA-WT breast cancer cells. (A) HCC1806
and T47D cells were treated with 1 mM AKTi-1/2 for the indicated times and cell lysates were immunoblotted with the indicated antibodies. (B)
HCC1806 and T47D cells were treated with 1 mM AKTi-1/2 or DMSO for 24 h. The fractions of cells in G1, S and G2/M were determined by flow
cytometry.
doi:10.1371/journal.pone.0003065.g002
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Furthermore, inhibition of Akt was accompanied by marked
dephosphorylation of Akt substrates and its downstream signaling
targets(GSK3,Foxo,p70S6K, S6 and 4EBP1) (Figure4A). Chronic
treatment with AKTi-1/2 caused a dose-dependent inhibition of
the growth of BT474 xenografts (Figure 4B); 100 mg/kg completely
suppressed the growth of the tumor with modest tumor regression,
whereas50 mg/kgonlydelayed tumorgrowth (Figure 4B; P,0.005
for 50 versus 100 mg/kg, and 50 and 100 mg/kg versus control).
Growth suppression in vivo was associated with loss of D-cyclin
expression, hypophosphorylation of Rb, a profound decrease in cell
proliferation as measured by Ki67, and induction of apoptosis as
measured by TUNEL and cleaved PARP (Figure 4A and 4C).
Similarly, AKTi-1/2 also effectively suppressed the growth of
PIK3CA(E545K)-mutated MCF7 xenografts (Figure 4D). Together,
these data show that chronic inhibition of Akt1 and Akt2 kinase can
be achieved in mice, at levels sufficient to recapitulate the Akt-
dependence of breast cancer cells with HER2 amplification or
PIK3CA mutation seen in vitro.
Herceptin-resistant breast cancer models are sensitive to
Akt inhibition
The anti-HER2 antibody Herceptin is effective for the treatment
of breast tumors with HER2 amplification [30], but patients with
metastatic disease invariably develop resistance to the antibody
[31,32]. The molecular mechanisms underlying resistance in
Figure 4. AKTi-1/2 effectively suppresses HER2-overexpressing and PIK3CA-mutated tumor growth in vivo. (A) AKTi-1/2 inhibits Akt
followed by dephosphorylation of its downstream targets (GSK3, Foxo, p70S6K, S6 and 4EBP1), loss of D-cyclin expression, Rb hypophosphrylation
and induction of PARP cleavage in BT474 xenograft tumors. Mice with established BT474 xenografts were treated with AKTi-1/2 100 mg/kg for the
indicated times. Tumor lysates were immunoblotted with the indicated antibodies. (B) Mice with established BT474 xenografts were treated with
AKTi-1/2 50 and 100 mg/kg/day65 days/week or vehicle only as control. The results represent the mean tumor volume6standard error (n=5 mice
per group) from two independent experiments. *, P,0.005, 50 versus 100 mg/kg AKTi-1/2, and 50 and 100 mg/kg AKTi-1/2 versus control. (C)
Representative immunohistochemistry fields of BT474 tumors from mice euthanized 6 h after the final treatment of AKTi-1/2 as in (B). Tumors were
excised, and H&E, phosphorylated Akt, Ki67 and TUNEL were assessed by immunohistochemic statining. (D) Mice with established MCF7 xenografts
were treated with AKTi-1/2 50 and 100 mg/kg/day65 days/week or vehicle only as control. The results represent the mean tumor volume6standard
error (n=5 mice per group) from two independent experiments. *, P,0.005, 50 versus 100 mg/kg AKTi-1/2, and 50 and 100 mg/kg AKTi-1/2 versus
control.
doi:10.1371/journal.pone.0003065.g004
Figure 3. Akt inhibition induces G1 arrest and apoptosis in HER2-overexpressing with or without PIK3CA-mutated breast cancer
cells. (A) Akt inhibition causes dephosphorylation of its downstream targets (Foxo1, GSK3a, p70S6K, S6 and 4EBP1), loss of D-cyclin expression, and
induction of p27 and PARP cleavage in BT474 and MDA-MB-453 cells treated with 1 mM AKTi-1/2. (B–C) Cells were analyzed by flow cytometry and
gated differently to determine fractions of G1, S and G2/M (B) and the fraction of apoptotic cells (sub-G1) (C). (B) Cells were treated with 1 mM AKTi-1/
2 or DMSO for 24 h. (C) Cells were treated with the indicated concentrations of AKTi-1/2 for 24 h, 48 h and 72 h. All error bars indicate standard error.
doi:10.1371/journal.pone.0003065.g003
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HER kinase inhibitor lapatinib in this setting suggests that a
significant proportion of Herceptin-resistant tumors remain HER2-
dependent [33]. To test the hypothesis that these tumors might also
remain dependent on Akt signaling, we used two experimental
models of Herceptin-resistant breast cancer: the BT474-EII cell line
model and the Fo5 xenograft model. BT474-EII was derived from
estrogen independent BT474 xenograft tumors that were found to
also be insensitive to Herceptin (Gail Phillips, Genentech, personal
communication). Herceptin and AKTi-1/2 both significantly
inhibited growth of HER2-overexpressing BT474 cells when
compared with untreated controls (P,0.001), with the latter being
somewhat more effective (Figure 5A). In contrast, Herceptin had no
effect on the growth of the resistant BT474:EII cell line (Figure 5A;
P=0.35), but the AKTi-1/2 was equally effective in the sensitive
and resistant model (Figure 5A; P,0.001 for AKTi-1/2 versus
control). The Fo5 model was derived from a transgenic MMTV-
human HER2-driven mouse after tumors maintained by serial
transplantation progressed during continuous Herceptin treatment
[34]. HER2 continues to be highly expressed in this tumor and
binds to Herceptin (Gail Phillips, Genentech, personal communi-
cation). Fo5 tumors were resistant to the anti-tumor effects of
Herceptin in vivo (Figure 5B; P=0.31). Treatment with AKTi-1/2
at dose of 100 mg/kg effectively inhibited phosphorylation of Akt
and its downstream targets (GSK3, Foxo, p70S6K, S6 and 4E-BP1)
in the Fo5 tumors for at least 12 hours (Figure 5D). Daily treatment
with AKTi-1/2 at this dose level for 4 weeks effectively inhibited
growth of the Fo5 xenografts (Figure 5C; P,0.001 for AKTi-1/2
versus control). Growth inhibition was associated with loss of D-
cyclin expression, induction of p27 and activation of caspase-3
(Figure 5D). These results suggest that HER2-dependent tumor
models with resistance to Herceptin remain dependent on Akt
signaling and that Akt inhibitors may be useful in treating
Herceptin-resistant breast cancer.
Discussion
The PI3K/Aktsignaling pathway is deregulated inthe majority of
human cancers and almost certainly plays an important pathogenic
role in carcinogenesis and progression. Data from model systems
suggest that inhibition of the pathway would both arrest growth and
induce apoptosis or sensitize the cell to proapoptotic stimuli [3].
Thus, much effort has focused on developing novel anti-tumor
agents that target this pathway. Up to now, however, it has been
unclear whether the degree of pathway inhibition required for
significant anti-tumor activity could be achieved without unaccept-
able toxicity. The PI3K/Akt pathway is an important regulator of
many key physiologic processes and the development of several
classes of Akt inhibitors has been halted because of toxicity [19,20].
We now show that a selective and potent allosteric inhibitor of
Akt1 and Akt2 effectively inhibits Akt signaling in tumor bearing
mice without gross toxicity or weight loss even when administered
chronically (Figures 4 and 5 and S2). The drug potently inhibits
Akt phosphorylation in breast cancers and inhibits the prolifera-
tion of breast tumors with PI3K mutation and/or HER2
amplification but is ineffective in tumors in which PI3K and
PTEN are wild-type and HER2 is expressed at normal levels.
Considering that the drug treatment is well tolerated and that
tumors in which the PI3K/Akt pathway is not mutationally
activated are insensitive to the drug, the hypersensitivity of tumors
with PI3K mutation or HER2 amplification suggests that these
tumors are ‘addicted’ to PI3K/Akt signaling.
Oncogene addiction is a term given for the observation that
inhibition of oncoprotein function in transformed cells often has
much more profound effects than inhibition of the corresponding
wild-type protein in the untransformed parental cell [35]. This
phenomenon has been noted in many systems and may be a general
property of oncoprotein-transformed cells, but the underlying
mechanism is not clear [36]. One possibility is that survival of
oncoprotein-transformed cells requires second mutations that
prevent senescence or apoptosis. In the context of these other
mutations, loss of function of the activated oncoprotein may be
selectively toxic [36]. A second possibility is that the complex
signaling network in normal cells is robust and relatively insensitive
to loss of any single component of the network. Constitutive
activation of the oncoprotein may feedback inhibit redundant
pathways in the network and cause the cell to become hyperdepen-
dent on the single oncoprotein. This idea is consistent with the
observation in Figures 2A and 3A, which show that Akt inhibition is
sufficient to inhibit key downstream signaling targets in tumors with
PI3K mutation or HER2 amplification, but not in those tumors with
wild-type PI3K and normal HER2 expression.
Akt (especially Akt2) is a key downstream mediator of the
metabolic effects of insulin and hyperglycemia is a known side-
effect of both PI3K and Akt inhibition [29,37]. The Akt1/Akt2
inhibitor caused transient and moderate hyperglycemia in mice
that is associated with a transient hyperinsulinemia (manuscript in
preparation). Why the drug is so effective at concentrations that
cause only transient hyperglycemia, but no gross toxicity, is not
entirely clear. It is possible that this is a manifestation of oncogene
addiction; the levels of pathway inhibition achieved are sufficient
to inhibit tumor growth, but without significant deleterious impact
on normal physiology. The inhibitor is equipotent against human
and mouse Akt in vitro and in vivo, ruling out selective inhibition
of the Akt in the xenograft tumor (unpublished data). The greater
selectivity of an allosteric inhibitor as compared to ATP-
competitive inhibitors may also play a role: off-target effects are
less likely. It is also possible that the relative sparing of Akt3
activity is responsible, although genetic models suggest that Akt2 is
most responsible for maintaining glucose homeostasis [29]. The
finding that the Akt1/Akt2 inhibitor can be given chronically to
animals for months without weight loss suggests that the drug does
not cause severe metabolic toxicity under these conditions, at least
in mice. Whereas the physiological function of Akt3 is unclear at
present, the avoidance of Akt3 inhibition may allow a greater
therapeutic window for Akt1 and Akt2 inhibition.
Whereas breast tumors with PI3K or HER2 deregulation may be
addicted to Akt signaling, the situation is less clear for tumors with
PTEN loss. ZR-75-1 (PTEN-negative, low EGFR) is extremely
sensitive to AKTi-1/2, but MDA-MB-468 (PTEN-negative, high
EGFR) is not. This could be due to a variety of factors, including
residual Akt3 activity in the latter cell line (Figure 1). However, this is
unlikely,since we have previouslyshownthat MDA-MB-468cellsare
not effectively inhibited when AKT activity is completely inhibited in
response to induction of the expression of wild type PTEN [28].
Triple negative breast tumors often have evidence for decreased
PTEN function together with elevated EGFR expression [15]. In
MDA-MB-468 cells, inhibition of either EGFR/MEK/ERK or
PI3K/Akt signaling alone has only modest effects on growth or
survival [28]. These and other data suggest that, in the context of
EGFR activation, the proliferation and survival of PTEN-negative
cells are not dependent on PI3K/Akt signaling alone. However,
inhibition of both pathways causes synergistic apoptosis and tumor
regression in vivo [28]. These data suggest that combined inhibition
of Akt and EGFR signaling may be a useful strategy for the treatment
of the triple-negative basal subset of breast cancers.
The results suggest that G1 progression and the survival of
breast tumors with PI3K mutation and/or HER2 amplification are
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PLoS ONE | www.plosone.org 7 August 2008 | Volume 3 | Issue 8 | e3065Figure 5. Herceptin-resistant HER2-overexpressing breast cancer cells retain Akt dependence. (A) Both Herceptin-sensitive (BT474) and
Herceptin-resistant (BT474:EII) HRE2-overexpressing breast cancer cells are sensitive to AKTi-1/2. Growth inhibition assays were performed as
described in Figure 1A. All error bars indicate standard error. *, P,0.001, Herceptin and AKTi-1/2 versus control in BT474 cells. **, P=0.35, Herceptin
versus control in BT474:EII cells. ***, P,0.001, AKTi-1/2 versus Herceptin and control in BT474:EII cells. (B) Herceptin has no anti-tumor effects on the
Fo5 xenograft model. Mice with established Fo5 tumors were treated with Herceptin 20 mg/kg/day62 days (Tue/Fri)/week or vehicle only as control.
The results represent the mean tumor volume6standard error (n=5 mice per group) from two independent experiments. *, P=0.31, Herceptin
versus control. (C) AKTi-1/2 demonstrates anti-tumor activity against the Herceptin-resistant Fo5 xenograft model. Mice with established Fo5 tumors
were treated with AKTi-1/2 100 mg/kg/day65 days/week or vehicle only as control. The results represent the mean tumor volume6standard error
(n=5 mice per group) from two independent experiments. *, P,0.001, AKTi-1/2 versus control. (D) Mice with established Fo5 tumors were treated
with AKTi-1/2 100 mg/kg for the indicated times. Tumor lysates were immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0003065.g005
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models selected for resistance to the anti-HER2 antibody
Herceptin retain Akt-dependence and their sensitivity to the drug.
These findings and the absence of gross toxicity in vivo suggest
that Akt inhibition is a feasible therapeutic strategy for breast
cancers in which PI3K/Akt signaling is dysregulated by mutation.
Up to now, effective inhibition of Akt signaling in tumors could
only be achieved with inhibitors of growth factor receptors (such as
HER2) known to drive the pathway in particular tumors. No agent
is currently available to directly and specifically inhibit Akt
signaling in breast and other cancers with PI3K mutation or PTEN
loss. Allosteric inhibition of Akt may be useful as a single modality
in the treatment of these tumors, including those that have become
resistant to HER2 inhibitors. Furthermore, it would be expected to
sensitize tumors to induction of apoptosis by cytotoxic agents and,
perhaps, in combination with EGFR inhibitors in triple-negative
breast cancer and with drugs such as rapamycin that cause the
feedback activation of PI3K/Akt signaling [38].
Materials and Methods
Cell culture and reagents
Human breast cancer cell lines were obtained from the
American Type Culture Collection (Manassas, VA) and main-
tained in a 1:1 mixture of DME:F12 medium supplemented with
4 mM glutamine, 100 units/ml each of penicillin and streptomy-
cin, and 10% heat-inactivated fetal bovine serum, and incubated
at 37uCi n5 %C O 2. HCC1143, HCC1419, HCC1428,
HCC1500 and HCC1806 were grown in RPMI 1640 with similar
supplements. The Herceptin-resistant breast cancer cell line
BT474-EII and the Fo5 tumors were obtained from Genentech
(South San Francisco, CA). The AKTi-1/2 [21] was obtained
from Merck (Whitehouse Station, NJ).
Cell proliferation assay
The effect of the drug on cell proliferation was determined using
a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega,
Madison, WI), which is based on quantification of the cellular
ATP level. Cells were plated in 96-well plates at a density of
2,000–5,000 cells in triplicates. The following day, cells were
treated with a range of drug concentrations prepared by serial
dilution. After 3–5 days of treatment, 100 ml of prepared reagent
was added to each well. The contents of the wells were mixed on a
plate shaker for 2 h, and then luminescence was measured by an
Analyst AD (Molecular Devices, Sunnyvale, CA).
Analysis of cell cycle and apoptosis
Cells were plated in 10 cm dishes and the following day cells were
treated with drug or vehicle (DMSO) for the indicated times. Both
adherent and floating cells were harvested, and the cell nuclei were
prepared by the method of Nusse [39], and cell cycle distribution
(G1, S, and G2/M) and proportion of apoptotic cells (sub-G1) were
determined by flow cytometric analysis of DNA content using red
fluorescence of 488 nm excited ethidium bromide-stained nuclei.
The cell cycle distribution and the fraction of apoptotic cells were
gated differently and determined separately in order to more easily
achieve accurate quantitation of each parameter.
Western blot analysis
Cells were washed with PBS once, disrupted on ice for 30 min in
NP-40 or RIPA lysis buffer as described [28] and cleared by
centrifugation. Protein concentration was determined with BCA
reagent (Pierce, Rockford, IL). Equal amounts of protein (10–50 mg)
in cell lysates were separated by SDS-PAGE, transferred to
membranes, immunoblotted with specific primary and secondary
antibodies and detected by chemiluminescence with the ECL
detection reagents (Amersham Biosciences, Piscataway, NJ). Anti-
bodies for p-Akt(S473), p-Akt(T308), p-GSK3a(S21), p-GSK3b(S9),
p-FOXO1(T24)/FOXO3(T32), p-p70S6K(T389), p-S6(S235/236),
p-S6(S240/244), p-4EBP1(T37/46), p-4EBP1(S65), p-4EBP1(T70),
Akt1, Akt2, pan-Akt, p-Rb(S780), p27, activated (cleaved) caspase-3
and cleaved PARP were from Cell Signaling Technology (Beverly,
MA). Akt3 antibody was from Upstate Biotechnology (Waltham,
MA). PTEN, Cyclin D1, Cyclin D2 and Cyclin D3 antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA). The HER2 (Ab-
15) antibody was from Neomarkers (Fremont, CA); EGFR antibody
was from BD Biosciences (San Jose, CA) and b-actin antibody was
from Sigma (St. Louis, MO).
Animal studies
Six-week-old nu/nu athymic female mice (NCI-Frederick Cancer
Center) were maintained in pressurized ventilated cages. Experi-
ments were carried out under an IACUC approved protocol and
institutional guidelines for the proper and humane use of animals in
research were followed. Tumors were generated by transplanting
0.5–1.0610
7 tumor cells in a 1:1 mixture of media and Matrigel (BD
Biosciences) into the right flank (200 ml/mouse). For the BT474 and
MCF7 models, 17b-estradiol pellets (0.72 mg/pellet) (Innovative
Research of America, Sarasota, FL) were inserted subcutaneously 3
daysbeforetumorcellinoculation.Forthe Fo5tumormodel,tumors
were serially passaged in nude mice and the tumors with 262m m
size were implanted subcutaneously. Prior to initiation of treatment,
mice were randomized to receive the AKTi-1/2 at a dose of 50 and
100 mg/kg or vehicle only as control. The AKTi-1/2 was
formulated in 25% hydroxypropyl b-cyclodextrin (pH 4–5), and
administered subcutaneously. Mice were killed by CO2 euthanasia.
The average tumor diameter (two perpendicular axes of the tumor
were measured) was measured in control and treated groups using a
caliper. The data are expressed as the increase or decrease in tumor
volumeinmm
3(mm
3=p/66(largerdiameter)6(smallerdiameter)
2).
To prepare lysates, tumor tissue was homogenized in 2% SDS lysis
buffer and then processed for Western blotting as described above.
For immunohistochemical studies, xenograft tumors were fixed
overnight in paraformaldehyde followed by dehydration in graded
ethanol and embedding in paraffin. 8 mm sections of tissue were
prepared for hematoxylin and eosin (H&E), Ki-67 and p-Akt(S473)
staining. TUNEL assay was performed using the In Situ Cell Death
Detection Kit (Roche Applied Science, Indianapolis, IN) according
to the manufacturer’s instructions.
Statistical analysis
Results are mean values6standard error. P-values are given in
the figure legends, and values of P . 0.05 were considered not to
be significant. Statistical analyses were performed by an unpaired,
two-tailed Student t-test.
Supporting Information
Figure S1 Sensitivity of additional breast cancer cell lines with
HER2 amplification or wild-type PIK3CA and PTEN to AKTi-1/2.
(A) Half-maximal growth inhibitory concentration (IC50)o fA K T i -
1/2 to HCC1143,HCC1428 andHCC1419breastcancer celllines.
Growth inhibition assays were performed as described in Figure 1A.
(B) Western blot analysis for expression of EGFR, HER2, Akt1,
Akt2, Akt3, total Akt, PTEN, b-actin and phosphorylated Akt at
Ser473 and Thr308 incelllysatesofthe indicated breast cancer cells.
(C)Westernblot analysisofSer473phosphorylatedAktandtotalAkt
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PLoS ONE | www.plosone.org 9 August 2008 | Volume 3 | Issue 8 | e3065in cell lysates of the indicated breast cancer cells after treatment with
various concentrations of AKTi-1/2 for 24 h.
Found at: doi:10.1371/journal.pone.0003065.s001 (0.63 MB TIF)
Figure S2 Chronic treatment with AKTi-1/2 does not cause
weight loss in mice. Mice with established BT474 (A) and Fo5 (B)
xenografts were treated with AKTi-1/2 50 and 100 mg/kg/
day65 days/week or vehicle only as control as described in
Figures 4B and 5C, respectively. The mouse body weight was
measured in control and treated groups using a weighing scale.
The results represent the mean body weight6standard error (n=5
mice per group) from two independent experiments.
Found at: doi:10.1371/journal.pone.0003065.s002 (0.14 MB TIF)
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